Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact
Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: MLST8

Gene summary for MLST8

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

MLST8

Gene ID

64223

Gene nameMTOR associated protein, LST8 homolog
Gene AliasGBL
Cytomap16p13.3
Gene Typeprotein-coding
GO ID

GO:0001932

UniProtAcc

Q9BVC4


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
64223MLST8LZE4THumanEsophagusESCC2.37e-061.68e-010.0811
64223MLST8LZE7THumanEsophagusESCC3.10e-074.08e-010.0667
64223MLST8LZE8THumanEsophagusESCC2.15e-142.34e-010.067
64223MLST8LZE20THumanEsophagusESCC1.16e-082.59e-010.0662
64223MLST8LZE22THumanEsophagusESCC4.40e-064.79e-010.068
64223MLST8LZE24THumanEsophagusESCC9.57e-153.78e-010.0596
64223MLST8LZE21THumanEsophagusESCC2.25e-052.39e-010.0655
64223MLST8LZE6THumanEsophagusESCC3.92e-031.52e-010.0845
64223MLST8P1T-EHumanEsophagusESCC1.87e-175.73e-010.0875
64223MLST8P2T-EHumanEsophagusESCC6.02e-671.20e+000.1177
64223MLST8P4T-EHumanEsophagusESCC2.32e-511.16e+000.1323
64223MLST8P5T-EHumanEsophagusESCC4.80e-254.72e-010.1327
64223MLST8P8T-EHumanEsophagusESCC1.62e-285.13e-010.0889
64223MLST8P9T-EHumanEsophagusESCC1.70e-162.90e-010.1131
64223MLST8P10T-EHumanEsophagusESCC9.54e-335.09e-010.116
64223MLST8P11T-EHumanEsophagusESCC7.46e-166.43e-010.1426
64223MLST8P12T-EHumanEsophagusESCC5.38e-439.07e-010.1122
64223MLST8P15T-EHumanEsophagusESCC7.32e-296.03e-010.1149
64223MLST8P16T-EHumanEsophagusESCC3.26e-264.97e-010.1153
64223MLST8P17T-EHumanEsophagusESCC9.88e-206.98e-010.1278
Page: 1 2 3 4 5 6 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
SkinThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AK: Actinic keratosis
cSCC: Cutaneous squamous cell carcinoma
SCCIS:squamous cell carcinoma in situ
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:0043254111EsophagusESCCregulation of protein-containing complex assembly278/8552428/187233.81e-162.77e-14278
GO:0031334111EsophagusESCCpositive regulation of protein-containing complex assembly166/8552237/187232.06e-141.07e-12166
GO:007190016EsophagusESCCregulation of protein serine/threonine kinase activity227/8552359/187231.12e-114.10e-10227
GO:1902905111EsophagusESCCpositive regulation of supramolecular fiber organization142/8552209/187235.51e-111.76e-09142
GO:1902903111EsophagusESCCregulation of supramolecular fiber organization237/8552383/187239.06e-112.75e-09237
GO:005149520EsophagusESCCpositive regulation of cytoskeleton organization147/8552226/187232.93e-096.38e-08147
GO:0051258111EsophagusESCCprotein polymerization183/8552297/187231.94e-083.75e-07183
GO:000701527EsophagusESCCactin filament organization259/8552442/187232.37e-084.50e-07259
GO:0032273111EsophagusESCCpositive regulation of protein polymerization95/8552138/187232.97e-085.57e-0795
GO:003253520EsophagusESCCregulation of cellular component size227/8552383/187234.77e-088.60e-07227
GO:0032970111EsophagusESCCregulation of actin filament-based process231/8552397/187232.91e-074.20e-06231
GO:0032956111EsophagusESCCregulation of actin cytoskeleton organization210/8552358/187234.40e-076.00e-06210
GO:0032271111EsophagusESCCregulation of protein polymerization143/8552233/187239.21e-071.17e-05143
GO:011005327EsophagusESCCregulation of actin filament organization166/8552278/187231.54e-061.85e-05166
GO:00719029EsophagusESCCpositive regulation of protein serine/threonine kinase activity124/8552200/187232.27e-062.61e-05124
GO:004586018EsophagusESCCpositive regulation of protein kinase activity219/8552386/187236.91e-066.97e-05219
GO:003367420EsophagusESCCpositive regulation of kinase activity260/8552467/187237.26e-067.22e-05260
GO:003083819EsophagusESCCpositive regulation of actin filament polymerization66/855299/187231.96e-051.72e-0466
GO:000815420EsophagusESCCactin polymerization or depolymerization130/8552218/187232.19e-051.88e-04130
GO:0030041110EsophagusESCCactin filament polymerization114/8552191/187236.46e-054.92e-04114
Page: 1 2 3 4 5 6 7 8 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
hsa04714211EsophagusESCCThermogenesis163/4205232/84659.22e-111.14e-095.86e-10163
hsa0414010EsophagusESCCAutophagy - animal101/4205141/84657.60e-086.21e-073.18e-07101
hsa041505EsophagusESCCmTOR signaling pathway98/4205156/84655.81e-041.95e-039.97e-0498
hsa041362EsophagusESCCAutophagy - other23/420532/84658.99e-032.14e-021.09e-0223
hsa041517EsophagusESCCPI3K-Akt signaling pathway197/4205354/84651.24e-022.83e-021.45e-02197
hsa04714310EsophagusESCCThermogenesis163/4205232/84659.22e-111.14e-095.86e-10163
hsa0414015EsophagusESCCAutophagy - animal101/4205141/84657.60e-086.21e-073.18e-07101
hsa0415013EsophagusESCCmTOR signaling pathway98/4205156/84655.81e-041.95e-039.97e-0498
hsa0413611EsophagusESCCAutophagy - other23/420532/84658.99e-032.14e-021.09e-0223
hsa0415114EsophagusESCCPI3K-Akt signaling pathway197/4205354/84651.24e-022.83e-021.45e-02197
hsa0471414LiverCirrhoticThermogenesis121/2530232/84655.70e-131.36e-118.36e-12121
hsa041406LiverCirrhoticAutophagy - animal65/2530141/84653.10e-052.47e-041.52e-0465
hsa0471415LiverCirrhoticThermogenesis121/2530232/84655.70e-131.36e-118.36e-12121
hsa0414011LiverCirrhoticAutophagy - animal65/2530141/84653.10e-052.47e-041.52e-0465
hsa0471422LiverHCCThermogenesis170/4020232/84655.36e-162.25e-141.25e-14170
hsa0414021LiverHCCAutophagy - animal99/4020141/84653.08e-084.70e-072.61e-0799
hsa041502LiverHCCmTOR signaling pathway95/4020156/84654.70e-041.99e-031.11e-0395
hsa0471432LiverHCCThermogenesis170/4020232/84655.36e-162.25e-141.25e-14170
hsa0414031LiverHCCAutophagy - animal99/4020141/84653.08e-084.70e-072.61e-0799
hsa0415011LiverHCCmTOR signaling pathway95/4020156/84654.70e-041.99e-031.11e-0395
Page: 1 2 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
MLST8SNVMissense_Mutationnovelc.706N>Ap.Ala236Thrp.A236TQ9BVC4protein_codingdeleterious(0.02)probably_damaging(0.968)TCGA-EA-A3HS-01Cervixcervical & endocervical cancerFemale<65I/IIUnknownUnknownSD
MLST8insertionFrame_Shift_Insnovelc.421_422insGCTGCATCTGTTACCGCCCTGAGGAGCACp.Ala141GlyfsTer27p.A141Gfs*27Q9BVC4protein_codingTCGA-DS-A1OA-01Cervixcervical & endocervical cancerFemale>=65I/IIChemotherapycarboplatinPD
MLST8SNVMissense_Mutationc.161N>Ap.Arg54Hisp.R54HQ9BVC4protein_codingdeleterious(0)possibly_damaging(0.772)TCGA-AU-6004-01Colorectumcolon adenocarcinomaFemale>=65I/IIUnknownUnknownSD
MLST8SNVMissense_Mutationc.258N>Tp.Lys86Asnp.K86NQ9BVC4protein_codingtolerated(0.22)possibly_damaging(0.772)TCGA-AG-A002-01Colorectumrectum adenocarcinomaMale<65I/IIUnknownUnknownSD
MLST8SNVMissense_Mutationnovelc.556N>Ap.Ala186Thrp.A186TQ9BVC4protein_codingdeleterious(0.01)possibly_damaging(0.625)TCGA-A5-A0G1-01Endometriumuterine corpus endometrioid carcinomaFemale>=65I/IIUnknownUnknownSD
MLST8SNVMissense_Mutationnovelc.46N>Ap.Ala16Thrp.A16TQ9BVC4protein_codingdeleterious(0.01)probably_damaging(0.946)TCGA-AJ-A3EK-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIChemotherapycarboplatinCR
MLST8SNVMissense_Mutationc.258G>Tp.Lys86Asnp.K86NQ9BVC4protein_codingtolerated(0.22)possibly_damaging(0.772)TCGA-AP-A1DV-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
MLST8SNVMissense_Mutationnovelc.691G>Ap.Asp231Asnp.D231NQ9BVC4protein_codingdeleterious(0.02)possibly_damaging(0.895)TCGA-AP-A1DV-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
MLST8SNVMissense_Mutationrs774913271c.661N>Tp.Arg221Cysp.R221CQ9BVC4protein_codingdeleterious(0)probably_damaging(0.939)TCGA-B5-A3FC-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
MLST8SNVMissense_Mutationc.743G>Tp.Arg248Metp.R248MQ9BVC4protein_codingdeleterious(0.01)possibly_damaging(0.905)TCGA-D1-A103-01Endometriumuterine corpus endometrioid carcinomaFemale>=65I/IIUnknownUnknownSD
Page: 1 2 3 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
64223MLST8KINASEinhibitorAZD8055AZD-8055
64223MLST8KINASEinhibitorMLN0128SAPANISERTIB
64223MLST8KINASEinhibitorOSI-027OSI-027
Page: 1